Calliditas Therapeutics AB (publ)

SSE:CALTX.ST

107.8 (SEK) • At close February 20, 2024
Bedrijfsnaam Calliditas Therapeutics AB (publ)
Symbool CALTX.ST
Munteenheid SEK
Prijs 107.8
Beurswaarde 5,785,850,440
Dividendpercentage 0%
52-weken bereik 80.8 - 141.9
Industrie Biotechnology
Sector Healthcare
CEO Ms. Renee Aguiar-Lucander
Website https://www.calliditas.se

An error occurred while fetching data.

Over Calliditas Therapeutics AB (publ)

Calliditas Therapeutics AB (publ), a clinical-stage biopharmaceutical company, focused on identifying, developing, and commercializing pharmaceuticals products for treatments in orphan indications with initial focus on renal and hepatic diseases. It offers Nefecon, an oral formulation of budesonide that is an immunosuppressant for the treatment of the autoimmune renal disease immunoglobulin

Vergelijkbare Aandelen

Ambea AB (publ) logo

Ambea AB (publ)

AMBEA.ST

57.2 SEK

Attendo AB (publ) logo

Attendo AB (publ)

ATT.ST

37.8 SEK

Bonesupport Holding AB (publ) logo

Bonesupport Holding AB (publ)

BONEX.ST

189.8 SEK

Probi AB (publ) logo

Probi AB (publ)

PROB.ST

203 SEK

Sedana Medical AB (publ) logo

Sedana Medical AB (publ)

SEDANA.ST

16.85 SEK

Genovis AB (publ.) logo

Genovis AB (publ.)

GENO.ST

43.5 SEK

Bactiguard Holding AB (publ) logo

Bactiguard Holding AB (publ)

BACTI-B.ST

84.4 SEK

BioArctic AB (publ) logo

BioArctic AB (publ)

BIOA-B.ST

227.8 SEK

Hansa Biopharma AB (publ) logo

Hansa Biopharma AB (publ)

HNSA.ST

32.64 SEK

BioInvent International AB (publ) logo

BioInvent International AB (publ)

BINV.ST

16.58 SEK

Financiële Gegevens

Cijfers zijn in miljoenen (SEK)

Cijfers zijn in miljoenen (SEK)